Around the world, physicians are seeking better treatments for COVID-19. What can they learn from cancer research? Today, STAT published an article written by Cancer Commons founder Marty Tenenbaum, PhD, in which he outlines how our strategy to learn from cancer patients who are trying treatments beyond the standard of care could also be applied to the coronavirus pandemic:
“This same rapid-learning approach can be used to improve treatment recommendations for patients with Covid-19, thousands of whom have already received dozens of off-label and compassionate-use therapies: hydroxychloroquine, remdesivir, sarilumab, and ivermectin, to name just a few. In the absence of a proven therapy, many patients with Covid-19 will receive experimental drugs outside the confines of randomized controlled trials. Some will recover, others will not. We can learn from all of them.”
This vision is already being put into action by our partner xCures through their BEAT19 initiative.